We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Rapid PCR Immunoassay Developed for Malaria Diagnosis

By LabMedica International staff writers
Posted on 29 Aug 2012
A polymerase chain reaction (PCR) immunoassay has been developed that detects the different malaria species and differentiates between Plasmodium falciparum and P. More...
vivax.

The test, which combines PCR with a nucleic acid lateral flow immunoassay (PCR-NALFIA) for amplicon detection, was thoroughly evaluated for the analytical sensitivity and specificity in the laboratory, the robustness, and reproducibility in a ring trial and accuracy and predictive value in a field trial.

Investigators at the Royal Tropical Institute (Amsterdam, The Netherlands) developed a PCR-NALFIA and tested its validity by analyzing 241 malaria positive and negative samples from travelers returning from malaria-endemic areas and samples provided by the Dutch blood bank considered negative for malaria. Also tested was a blood sample from Sudanese patients with a confirmed P. falciparum infection. Accuracy was evaluated in Thailand and compared to expert microscopy and rapid diagnostic tests (RDTs). A nitrocellulose membrane of 120 mm (Millipore, Amsterdam, The Netherlands) was used for the preparation of the NALFIA.

The analytical sensitivity and specificity were very high, but were slightly less sensitive for the detection of P. vivax than for P. falciparum. The reproducibility tested in three laboratories was very good, though this evaluation showed that the PCR machine used could influence the results. In the field trial in Thailand, the overall and P. falciparum-specific sensitivity and specificity was good ranging from 0.86-1 and 0.95-0.98 respectively, compared to microscopy. P. vivax detection was better than the sensitivity of RDT, but slightly less than microscopy performed in this study.

The authors concluded that the assay in its current format, or slightly modified with more sensitive detection of P. vivax, could be an excellent tool for epidemiological studies on prevalence or distribution of parasites. In addition, it could be used as a screening tool at regional level for malaria control programs, especially in countries with declining transmission. Molecular tools have been shown to be especially valuable in areas where there is moderate to little transmission and PCR-NALFIA could be a usable simple method in these settings. The study was published on August 17, 2012, in the Malaria Journal.

Related Links:

Royal Tropical Institute
Millipore



Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Automated Staining Unit
RAL Stainer
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.